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In prostate cancer (PCa), abnormal expression of several microRNAs (miRNAs) has been reported. 
Increasing evidence shows that aberrant epigenetic regulation of miRNAs is a contributing factor to 
their altered expression in cancer. In this study, we investigated whether expression of miR-205 in 
PCa is related to the DNA methylation status of its promoter and locus region. 
PCR analysis of miR-205 expression was performed in PCa cell-lines and clinical specimens. CpG 
methylation analysis of the miR-205 promoter and miR-205 locus was performed in PCa cell-lines 
and clinical specimens via pyrosequencing. The effect on promoter and locus methylation status in 
cells treated with demethylating agents including 5-aza-2’deoxycytidine (decitabine), knockdown of 
DNA methyltransferase 1 (DNMT1) and knockdown of enhancer of zeste homolog 2 (EZH2) was 
also examined. Finally, the biological significance of miR-205 in PCa cells was assessed using in 
vitro bioassays. 
miR-205 was significantly down-regulated across PCa cell-lines. This correlated inversely with the 
methylation status of the miR-205 promoter and miR-205 locus, which is hypermethylated across 
this panel of cell-lines in both regions. Interestingly, a trend towards an inverse correlation was 
evident between miR-205 methylation, for both regions, and miR-205 expression levels in clinical 
specimens. Moreover, in PC3 cells, miR-205 expression was subsequently elevated by treatment 
with demethylating agents suggesting its expression is regulated by methylation. miR-205 promoter 
and locus methylation status, following treatment with 5-aza-2 deoxycytidine in PC3 cells, showed 
no change in methylation levels in either region. Finally, over-expression of miR-205 in PC3 cells 
inhibited growth and clonogenic potential, as well as inducing apoptosis.  
Preliminary findings provide evidence that miR-205 is abnormally expressed in PCa and appears to 
have a tumour suppressor role in PCa. This study investigated the role of DNA methylation in 
regulating miR-205 expression. It is evident that DNA methylation of the regions analysed may not 
be responsible for regulating miR-205 expression; thus, other regions within the promoter and locus 
regions, which have not been identified, may be more important. Furthermore, histone modifications 
may have a role, alongside DNA methylation, in regulating miR-205 expression. Future work entails 
investigating the biological and prognostic value of miR-205 in PCa. 
  
